|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Ticagrelor#Adult Indications and Dosage]] |
| {{Ticagrelor}}
| |
| {{CMG}}; {{AE}} {{JH}}
| |
| | |
| ==Indications and Usage==
| |
| | |
| ====Acute Coronary Syndromes====
| |
| | |
| BRILINTA is a [[P2Y12]] platelet inhibitor indicated to reduce the rate of thrombotic cardiovascular events in patients with [[acute coronary syndrome|acute coronary syndrome (ACS)]] ([[unstable angina]], [[NSTEMI|non-ST elevation myocardial infarction]], or [[ST elevation myocardial infarction]]). BRILINTA has been shown to reduce the rate of a combined endpoint of cardiovascular death, [[myocardial infarction]] or [[stroke]] compared to [[clopidogrel]]. The difference between treatments was driven by CV death and [[MI]] with no difference in [[stroke]]. In patients treated with [[PCI]], it also reduces the rate of stent [[thrombosis]] ''[see [[Ticagrelor clinical studies|Clinical Studies]]]''.
| |
| | |
| BRILINTA has been studied in ACS in combination with [[aspirin]]. Maintenance doses of [[aspirin]] above 100 mg decreased the effectiveness of BRILINTA. Avoid maintenance doses of [[aspirin]] above 100 mg daily ''[see [[Ticagrelor warnings and precautions|Warnings and Precautions]] and [[Ticagrelor clinical studies|Clinical Studies]]]''.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = BRILINTA (TICAGRELOR) TABLET [ASTRAZENECA LP] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f7b3f443-e83d-4bf2-0e96-023448fed9a8 | publisher = | date = | accessdate = }}</ref>
| |
| | |
| ==References==
| |
| | |
| {{Reflist|2}}
| |
| | |
| [[Category:ADP receptor inhibitors]]
| |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |